|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-1.12/1.34
|
企业价值
760.23M
|
资产负债 |
每股账面净值
10.34
|
现金流量 |
现金流量率
--
|
损益表 |
收益
157.75M
|
每股收益
9.76
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/07 04:16 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19. |